ProKidney Corp. Class A Ordinary Shares PROK · Stock Open ProKidney Corp. Class A Ordinary Shares in new tab
ProKidney Corp. Class A Ordinary Shares Analysis (PROK)
Is ProKidney Corp. Class A Ordinary Shares a good investment? ProKidney Corp. Class A Ordinary Shares (PROK) is currently trading at 1.56 USD. Market analysts have a consensus price target of 6.25 USD. This suggests a potential upside from current levels.
Earnings Schedule: ProKidney Corp. Class A Ordinary Shares is expected to release its next earnings report on Aug. 6, 2026. The market consensus estimate for Forward EPS is -0.58.
Investor FAQ
Does ProKidney Corp. Class A Ordinary Shares pay a dividend?
No, it does not currently pay a dividend.
What asset class is ProKidney Corp. Class A Ordinary Shares?
ProKidney Corp. Class A Ordinary Shares is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Aug. 6, 2026. The company currently has a trailing EPS of -0.54.
Company Profile
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Community Discussion